✦ LIBER ✦

Parkinson's disease and the environment in early life

✍ Scribed by C.N. Martyn; C. Osmond

Book ID: 118932290
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 643 KB
Volume: 132
Category: Article
ISSN: 0022-510X
DOI: 10.1016/0022-510x(95)00148-u

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Parkinson’s Disease, Environment and Gen

Parkinson’s Disease, Environment and Genes

✍ Joan M Cranmer 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 247 KB

Parkinson’s Disease, Environment and Gen

Parkinson’s Disease, Environment and Genes

✍ Joan M Cranmer 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Prenatal and early life factors and risk

Prenatal and early life factors and risk of Parkinson's disease

✍ Hannah Gardener; Xiang Gao; Honglei Chen; Michael A. Schwarzschild; Donna Spiege 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Abstract Few studies have investigated the relation between early life factors and risk of Parkinson's disease (PD), although a potential role of exposures during pregnancy and childhood has been hypothesized. The study population comprised participants in two prospective cohorts: the Nurses' He

Parkinson's disease and the environment:

Parkinson's disease and the environment: Beyond pesticides

✍ W. Michael Caudle; Thomas S. Guillot; Carlos Lazo; Gary W. Miller 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Gene–environment interactions in Parkins

Gene–environment interactions in Parkinson's disease

✍ Christopher A. Ross; Wanli W. Smith 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 324 KB

Rasagiline improves quality of life in p

Rasagiline improves quality of life in patients with early Parkinson's disease

✍ Kevin M. Biglan; Steven Schwid; Shirley Eberly; Karen Blindauer; Stanley Fahn; T 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early P